ArticleCancer reports (Hoboken, N.J.)2026
Impact of Metformin Use on Clinical and Pathological Outcomes in Breast Cancer Patients With Type 2 Diabetes.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBreast cancer is the most common malignancy in women, and its incidence is increasing worldwide. Type 2 diabetes mellitus (T2DM) is a significant comorbidity in patients with breast cancer that negatively affects prognosis. Metformin, a first-line antidiabetic drug, has been suggested to possess antineoplastic properties. This study investigated the effects of metformin on the demographic characteristics, pathological parameters, treatment response, and prognosis of breast cancer patients with T2DM in an Iranian population.
methodsA retrospective cross-sectional study was conducted on 104 patients with breast cancer and T2DM at the Velayat Educational and Therapeutic Center, Qazvin, Iran, from 2019 to 2023. The patients were categorized into two groups: metformin users (n = 46) and non-users (n = 58). Data on demographic characteristics, disease stage, lymph node involvement, hormone receptor status, treatment response, prognosis, recurrence, and metastasis were collected. Statistical analyses were performed using SPSS version 25, with significance set at p < 0.05. Unadjusted and adjusted logistic regression analyses were performed to identify independent predictors of prognosis.
resultsThe mean disease duration was significantly shorter in the metformin group than in the non-metformin group (p = 0.036). A significant difference was observed in the stage of disease (p = 0.003), with metformin users more frequently presenting at earlier stages. Lymph node involvement was significantly lower in the metformin group (p = 0.008). Patients using metformin showed significantly better treatment response (p = 0.028) and prognosis (p = 0.009). However, no significant differences were observed in the estrogen receptor (ER) status (p = 0.293), human epidermal growth factor receptor 2 (HER2) status (p = 0.762), metastasis (p = 0.249), or recurrence rates (p = 0.770). After adjustment, disease duration, HER2 status, and metformin use remained independently associated with prognosis.
conclusionMetformin use in breast cancer patients with T2DM is associated with lower disease stage, fewer involved lymph nodes, improved treatment response, and better prognosis. These findings suggest that metformin may play a beneficial role in breast cancer progression and treatment outcomes. Further prospective studies are warranted to confirm these results in a clinical setting and to elucidate the underlying mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.